382 Preliminary efficacy and tolerance results of docetaxel (taxotere) (TXT) in heavily pretreated metastatic breast cancer patients (MBC)

The activity/safety profile of TXT in heavily pretreated MB pts is of interest to the practicing oncologist. Pts char From Aug 1994 to Feb 1995, 29 women with heavily pretreated MBC, have received TXT: 24 pts with 100 mg/and 5 pts with 70 mg/sqm q 3 weeks given with steroids premedication: median age 53 years [42–75]; PS (WHO) 0–1: 16 pts (55%), 2: 9 pts (31%), 3: 4 pts (14%), median time diagnosis first relapse: 28 months (m) [1–216]; median time first relapse/TXT: 40 m [1–164]; Metastatic Sites: liver: 17 pts (58%), bone: 16 pts (55%), lung: 14 pts (48%), skin: 12 pts (41%), lymph nodes: 2 pts (6%), CNS: 4 pts (14%), miscellaneous: 1 (3%). Number of sites/pt: 1: 6 pts (20%), 2: 13 pts (45%), ≥ 3: 9 pts (31%); CA 15-3 was increased in 20 pts (68%). Median nb previous chemotherapy (CT) Unes: 4 [2-11], with anthracyclines 27 pts (93%); 16pts (55%) had also Mitoxantrone; previous hormonotherapy in 25 pts (86%). Toxicity 123 cycles (cy); median (cy) nb/pt: 4 [1–10]; 84 (cy) and 28 (pts) evaluable for hematol Tox, 13 cy (23%) grade III and 44 cy (52%) grade IV neutropenia, 5 cy (6%) grade III–IV thrombocytopenia; 106 cy and 28 pts evaluable for non hematol Tox: asthenia (100%); 5 episodes of mucositis grade III, other Tox: edema: 15 pts (53%) (1 severe); nail changes: 12 pts (42%). Activity 22 pts evaluable (2 early death and 5 too early): 4 PR (6+, 7+, 7+, 8), 11 Minor Response, 7 PD. Median TIP (all pts) 3 months (1–8). Encouraging results and acceptable toxicity in a multitreated cohort confirm the value of TXT and its interest as second or first line treatment in MBC.